Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciencesFRA:82P -1.87%77 EV-to-EBITDA is 9.85 as of Sep. 20, 2026, which is 55% below its 10-year median of 21.69. GuruFocus rates FRA:82P with a GF Score™ of 77/100 and a GF Value™ of €25.01. The stock has 7 warning signs investors should review. Among 746 Drug Manufacturers companies, Pacira BioSciences ranks better than 61.13% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pacira BioSciences's enterprise value is €998.4 Mil.
Pacira BioSciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €101.4 Mil. Therefore, Pacira BioSciences's EV-to-EBITDA for today is 9.85.
The historical rank and industry rank for Pacira BioSciences's EV-to-EBITDA or its related term are showing as below:
FRA:82P'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1950.78 Med: 21.69 Max: 186.32
Current: 9.97
During the past 13 years, the highest EV-to-EBITDA of Pacira BioSciences was 186.32. The lowest was -1950.78. And the median was 21.69.
FRA:82P's EV-to-EBITDA is ranked better than 61.13% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.395
vs FRA:82P: 9.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pacira BioSciences's PE Ratio (TTM) for today is calculated as:
Pacira BioSciences's share price for today is €21.00.
Pacira BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.298.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pacira BioSciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs AMPH, COLL, IRWD: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's EV-to-EBITDA falls into.
Pacira BioSciences's current Enterprise Value is €998.4 Mil.
Pacira BioSciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €101.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a EV-to-EBITDA of 9.85 as of Sep. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pacira BioSciences. This is 55% below median its historical median of 21.69. According to the industry distribution chart, Pacira BioSciences ranks #290 out of 746 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Pacira BioSciences' EV-to-EBITDA too high?
Pacira BioSciences' current EV-to-EBITDA of 9.85 is 55% below median its 10-year median of 21.69. The Drug Manufacturers industry median EV-to-EBITDA is 12.40. Pacira BioSciences' value of 9.85 is 20.5% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #290 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' EV-to-EBITDA compare to AMPH and COLL?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #290 out of 746 companies for EV-to-EBITDA. This puts Pacira BioSciences in the upper half of its industry. The industry median EV-to-EBITDA is 12.40. Pacira BioSciences' value of 9.85 is 20.5% below this benchmark. While the company's 10-year median is 21.69 vs. the industry median of 12.40, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.40, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current EV-to-EBITDA of 9.85 is 20.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pacira BioSciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current EV-to-EBITDA is 9.85, which is 55% below median its own 10-year median of 21.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current EV-to-EBITDA of 9.85. The stock's GF Value™ is €25.01, compared to a current price of €21.00 — trading 16% below its estimated fair value. The current EV-to-EBITDA is 9.85, which is 55% below median its 10-year median of 21.69 and 20.5% below the Drug Manufacturers industry median of 12.40. Pacira BioSciences' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current EV-to-EBITDA is 9.85 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €21.00 is trading 16% below its estimated GF Value™ of €25.01.
Key valuation signals for FRA:82P:
EV-to-EBITDA: 9.85 (55% below median its 10-year median of 21.69)
GF Value™: €25.01 vs. price of €21.00 (16% below fair value)
Industry Position: 20.5% below the Drug Manufacturers median (#290 of 746)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
77GF Score
Get the complete analysis for FRA:82P
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
